Trial · NCT02699073
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
NCT02699073, Phase 2, Completed, GERCOR - Multidisciplinary Oncology Cooperative Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib. Trials, record NCT02699073. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02699073
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
- NCT number
- NCT02699073
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- regorafenib
- First posted
- 2016-03-04
- Last updated
- 2019-02-28
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor response rate at 2 months according Choi Criteria | 2 months after the beginning of treatment | |
| Secondary | Tumor response rate at 1 and 2 months according to RECIST1.1 | At 1 month and 2 months after the beginning of treatment | |
| Secondary | Tumor response rate at 1 month according to Choi criteria | At 1 month after the beginning of treatment | |
| Secondary | Best overall response rate (BOR) according to Choi criteria and to RECIST 1.1 | BOR is the best response recorded from the strat of treatment until treatment failure up to 36 months | |
| Secondary | Disease control rate (DCR) | DCR is the proportion of patient with tumor response (CR or RP) or tumor stabilization as best response from the inclusion until treatment failure, up to 36 months | |
| Secondary | Overall Survival (OS) | Assessed from the date of study drug start to the date of patient death, due to any cause or to the last date the patient was known to be alive, up to 36 months | |
| Secondary | Progression free survival (PFS) | PFS is the time from the date of study drug start to the date of progressive disease or death due to any cause, up to 36 months | |
| Secondary | Specificity of Choi criteria at 1 month in identifying patients with long or short OS (using median OS as cut-off value). | At 1 month after inclusion | |
| Secondary | Evaluation of tumor heterogeneity with TexRAD software | At baseline and 1 month after inclusion | Threshold of the CTTA parameters (Skewness, Kurtosis, Entropy, Uniformity) provided by the TexRAD software at baseline and optimal variations of these parameters on the CT performed at one month (compared to baseline). |
| Secondary | Serious adverse events( SAE) and adverse event (AE) | Up to 36 months | assessed by NCI-CTCAE4.0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02699073
GET https://conductscience.org/api/trials/v1/NCT02699073/registered